Discover trends, market shifts, and competitive outlooks for the polymyalgia rheumatica industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Anticipated CAGR of the Polymyalgia Rheumatica Market, and What Factors Will Drive It?

In the past few years, the polymyalgia rheumatica market size has witnessed significant growth. The projection is that it will expand from $1.28 billion in 2024 to $1.36 billion in 2025 with a compound annual growth rate (CAGR) of 6.6%. Factors that contributed to this historical growth include heightened awareness among healthcare professionals, increased utilization of corticosteroids, proliferation of specialty clinics, the advent of biologic therapies, and boosted healthcare budgets.

Strong expansion is anticipated in the polymyalgia rheumatica market in the coming years, with predictions estimating its value will reach $1.73 billion in 2029, stemming from a compound annual growth rate (CAGR) of 6.2%. This predicted increases are mainly due to the increased use of biologics, the broadening of precision medicine, an acceleration in drug approvals, more comprehensive reimbursements, and an enlargement in clinical trials. During the forecast period, key trends are expected to be the creation of combination therapies, breakthroughs in personalized medicine, precision medicine development, the inclusion of electronic health records, as well as progress in biomarkers.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

What External and Internal Drivers Are Contributing to the Growth of the Polymyalgia Rheumatica Market?

The ascension in demand for tailored medical treatment, known as personalized medicine, is anticipated to boost the expansion of the polymyalgia rheumatica market. This individual-oriented medicine approach, influenced by an individual’s unique genetic makeup, lifestyle, and personal health state, brings more effective results. This personalized medical revolution has been propelled by progressive genetic studies, rising patient desires for bespoke treatment plans, and technological improvements in diagnostics. Understanding individual genetic variations through genetic studies has allowed for the creation of customized treatments targeting specific genetic markers. This individualized approach to medicine aids in drug selection, based on patient’s unique characteristics for a safer and more effective treatment agenda. For instance, the Personalised Medicine Coalition, a health care organisation based in the US, reported that in February 2024, the Food and Drug Administration approved 16 new bespoke treatments for rare disease patients in 2023, as compared to six in 2022. This surge in personalized medicine subsequently maneuvering the growth of the polymyalgia rheumatica market. As the ascension in telemedicine services is anticipated to encourage the expansion of the polymyalgia rheumatica market. Telemedicine services utilize digital communicative technologies, such as video and phone calls and online chatting, to extend remote medical consultations, diagnoses, treatment, and patients’ post-treatment care without the requirement of physical appointments. This ascension in telemedicine services is a response to rising demand for convenient and economical healthcare solutions. Telemedicine eradicates the necessity for physical appointments, offering convenience particularly for non-urgent consultations. The growth of these remote healthcare services is beneficial for managing polymyalgia rheumatica (PMR) as it enables distant symptom tracking, medication supervision, and regular patient follow-ups, all essential for managing long-lasting pain and inflammation. For example, the Australian Bureau of Statistics, a governmental agency based in Australia, reported in November 2024 that the proportion of individuals using telehealth consultations rose from 87.7% in 2022-23 to 89.2% in 2023-24. The escalating use of telemedicine services subsequently contributes to the expansion of the polymyalgia rheumatica market.

What Segment Types Define the Polymyalgia Rheumatica Market Structure?

The polymyalgia rheumatica market covered in this report is segmented –

1) By Treatment: Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Biologics

2) By Route Of Administration: Oral, Intravenous, Subcutaneous

3) By Patient Type: Adult, Geriatric, Periatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Aspirin, Celecoxib

3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine

4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-6 (IL-6) Inhibitors, B-Cell Inhibitors, Janus Kinase (JAK) Inhibitors

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Polymyalgia Rheumatica Market?

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Polymyalgia Rheumatica Market?

Notable companies navigating the polymyalgia rheumatica market are prioritizing the creation of advanced medicinal treatments, particularly interleukin-6 (IL-6) receptor blockers, which offer a more precise, effective mode of action. These biological therapeutics function by inhibiting IL-6, an integral pro-inflammatory cytokine in the context of autoimmune diseases. By obstructing IL-6, these interventions create a cascade of effects that decrease inflammation and ameliorate symptoms, improving life quality for those suffering from PMR. As an example, Regeneron Pharmaceuticals Inc., originating from the U.S., and Sanofi, a healthcare enterprise based in France, publicly stated in February 2023 that the FDA had approved their joint product, Kevzara (sarilumab), for the treatment of polymyalgia rheumatica in adults who are not optimally responsive to corticosteroids or who have trouble easing off them. Kevzara is singular in its status as the first and only biological agent approved for this condition, and it accomplishes its therapeutic goal by interfering with IL-6-mediated signaling. This approval was fueled by the results of a trial where 28.3% of patients under sarilumab obtained sustained remission by the 52nd week, as opposed to only the 10.3% who were given a placebo. The treatment protocol for Kevzara involves a subcutaneous injection every fortnight, and it carries an additional approval for the management of moderately to severely active rheumatoid arthritis. Sanofi’s shares (SNY) are presently valued at $54.13 on the NASDAQ market.

View the full report here:

https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

What Is the Definition of the Polymyalgia Rheumatica Market?

Polymyalgia rheumatica (PMR) is an inflammatory disorder that primarily affects older adults, causing muscle pain and stiffness, particularly in the shoulders, hips, and neck. It is characterized by aching and swelling in the muscles around the shoulders and hips, leading to difficulty in movement and daily activities.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22103

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model